Pharmafile Logo
Pharmafocus logo
Advanced Search

Health reforms will do ‘irreparable’ damage to public health

October 4, 2011
NHS reforms

Doctors have urged the House of Lords to reject the Health and Social Care Bill, saying the proposed legislation will …

News
adaptimmune_helen_tm1

Adaptimmune makes board appointments

October 4, 2011
Manufacturing and Production, Research and Development appointment, manufacturing and production, research and development

UK and US-based cell therapy company Adaptimmune has made two new appointments to its board. Dr Jonathan Knowles joins as …

Appointment
Roche Nutley

Manufacturing makes a comeback at Roche’s Nutley site

October 4, 2011
Manufacturing and Production Roche, pharma manufacturing news

Roche has opened a new manufacturing facility at its campus in Nutley, New Jersey, that will supply dosage forms for …

News

Merck pays $1.5m penalty for US pollution

October 4, 2011
Manufacturing and Production Merck & Co, pharma manufacturing news

Merck & Co has fallen foul of US regulations on environmental controls at two manufacturing plants and agreed to pay …

News

Digital Pharma: NHS-backed health social network launches

October 3, 2011
Medical Communications Digital Pharma blog, NHS, social media

A new NHS-backed social network has launched to provide support to patients with long-term conditions through ‘personal health planning’. How …

News

Pharma manufacturing news in brief

October 3, 2011
Manufacturing and Production pharma manufacturing news

Our round-up of pharma manufacturing news sees a green energy drive from GSK, facility updates from Stirling Pharma, Reckitt Benckiser …

News
Takeda

Takeda completes Nycomed acquisition, installs new chief executive

October 3, 2011
Sales and Marketing Nycomed, Takeda

Takeda Pharmaceutical Company has completed its acquisition of Nycomed and named Frank Morich as chief executive of the Zurich-based firm. …

News

Trial disappointment for AZ lung cancer drug

October 3, 2011
Research and Development, Sales and Marketing AstraZeneca, selumetinib

AstraZeneca’s lung cancer drug selumetinib has failed to hit its primary endpoint in a Phase II trial. The trial compared …

News

SHL receives Good Design Award for Molly Auto Injector

October 3, 2011
Manufacturing and Production auto injector, autoinjector, good design award, molly

SHL Group is honored to have recently received certification for the Good Design Award for its revolutionary auto injector, Molly. …

News
Press release

Jean-Pierre Garnier elected chairman of Actelion

October 3, 2011
Sales and Marketing appointment, sales and marketing

Jean-Pierre Garnier has been elected chairman of Swiss biopharmaceutical company Actelion. He has sat on the company’s board since May …

Appointment

Chinese API supplier under FDA scrutiny

October 3, 2011
Manufacturing and Production Sichuan Pharmaceutical, pharma manufacturing news

Chinese active ingredient manufacturer Sichuan Pharmaceutical has been sent a warning by the US FDA for failing to sort out …

News
Janssen's Psoriasis 360 campaign

Janssen repeats digital award success

September 30, 2011
Medical Communications PM Society Digital Awards

Janssen was once again the standout winner at last night’s PM Society’s Digital Media Awards. The pharma company beat its …

News
GSK

NICE says no to lupus treatment

September 30, 2011
Sales and Marketing Benylsta, GSK, Lupus, NICE

NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …

News

Chiltern expands North American Operation with a new office in Illinois

September 30, 2011
Research and Development

 Mr. Barry Simms, Chiltern’s Country Manager, North America, commented, “Chiltern continues to look for opportunities to increase our strategic footprint …

News
Press release

Astellas abandons oral anticoagulant darexaban

September 30, 2011
Research and Development Astellas, Eliquis, Xarelto, darexaban

Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …

News

NICE refuses to back Sanofi’s Jevtana

September 30, 2011
Sales and Marketing Jevtana, NICE

NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …

News

R&D jobs in emerging markets – leaders wanted

September 29, 2011
Business Services, Research and Development Jobs, careers, pharma jobs

The globalisation of pharmaceutical research and development is creating a wave of job opportunities in emerging markets such as India …

Feature
Merck & Co

Merck pulls out of J&J consumer venture

September 29, 2011
Sales and Marketing J&J, JJ, Merc & Co, OTC

Merck & Co has exited a joint venture with J&J, selling its stake in the J&J/Merck Consumer Pharmaceuticals business to …

News

NICE blames pharma R&D model for spiralling cancer drug costs

September 29, 2011
Research and Development, Sales and Marketing Cancer, NICE, clincial trials

NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …

News
Novartis

Novartis’ brain tumour drug Votubia launched in UK

September 29, 2011
Sales and Marketing Afinitor, Votubia

Novartis has launched its orphan drug Votubia in the UK for patients with a rare type of brain tumour. Votubia …

News
The Gateway to Local Adoption Series

Latest content

Alto Neuroscience announces new patent for depression treatment

January 15, 2026

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project

January 14, 2026

Biocartis announces breast cancer research collaboration with US Mayo Clinic

January 14, 2026

Blue Earth announces first UK patient received prostate cancer injection

January 13, 2026